Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of the organ without worsening the condition.
BELIEBTE BEITRÄGE
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
A banana wrapped in duct tape sells for $6.2 million at auction
November 22, 2024
LIVEÜBERTRAGUNG